期刊
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
卷 39, 期 4, 页码 294-300出版社
INFORMA HEALTHCARE
DOI: 10.1080/00365590510031228
关键词
cardiovascular complications; parenteral estrogen; progression; prostatic cancer; therapy
Objective. To evaluate the cardiovascular ( CV) complications associated with orchiectomy ( OE) and parenteral polyestradiol phosphate ( PEP) therapy ( 240 mg/ month), taking into account the effect of pretreatment diseases and pretreatment medication. Material and methods. A total of 244 T3 - 4 M0 patients and 200 T1 - 4 M1 patients were randomized to either OE or PEP therapy. The two groups of patients were analyzed separately. The follow- up period was 36 months. The effect of pretreatment vascular and other diseases and pretreatment medication which may be associated with a risk of CV complications was evaluated. Results. In the T3 -/ 4 M0 patients, the treatment ( PEP versus OE) and the presence of pretreatment vascular diseases were statistically significantly associated with a risk of CV complications ( p = 0.01 and 0.003, respectively). In the T1 - 4 M1 patients, such an association was not found. No association was observed between pretreatment medication and CV complications. There was no difference in progression- free time between the therapy groups in either the T3 - 4 M0 or T1 - 4 M1 patients. Conclusion. In patients with locally advanced prostatic cancer, PEP therapy is associated with a statistically significantly higher risk of CV complications compared to OE.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据